Table 3.
Presumptive diagnosis at endoscopy | 2019 | 2020 | Percentage decrease | p-value |
---|---|---|---|---|
IBD | ||||
Total | 258 | 218 | −15.5% | 0.210 |
Median (IQR) | 7 (11) | 7 (10) | ||
HP Gastritis | ||||
Total | 207 | 122 | −41.1% | 0.001* |
Median (IQR) | 3 (9) | 2 (4) | ||
Eosinophilic Gastroenteropathy | ||||
Total | 129 | 63 | −51.2% | 0.001* |
Median (IQR) | 2 (5) | 1 (3) | ||
GERD | ||||
Total | 291 | 133 | −54.3% | <0.001* |
Median (IQR) | 7 (13) | 2 (7) | ||
Celiac Disease | ||||
Total | 621 | 279 | −55.1% | <0.001* |
Median (IQR) | 27 (27) | 8 (9) | ||
FGID | ||||
Total | 417 | 175 | −58.0% | 0.003* |
Median (IQR) | 9 (19) | 3(9) | ||
Main indication for follow-up endoscopy | ||||
IBD, disease flare | 0.223 | |||
Total | 292 | 244 | −16.4% | |
Median (IQR) | 9 (14) | 6 (7) | ||
IBD, mucosal healing assessment | 0.001* | |||
Total | 211 | 109 | −48.3% | |
Median (IQR) | 5 (13) | 1 (7) | ||
Eosinophilic gastroentheropaty | 0.002* | |||
Total | 194 | 90 | −53.6% | |
Median (IQR) | 5 (12) | 2 (5) | ||
GERD | 0.005* | |||
Total | 139 | 50 | −64.0% | |
Median (IQR) | 2 (7) | 0 (3) |
*Below the threshold of statistical significance (p = 0.05).